Corporate documents

Strategic plan

View Hepatitis Australia's Strategic Plan Read more

View Hepatitis Australia's Annual Reports Read more

Parliamentary Morning Tea: We can eliminate hepatitis C!

The Parliamentary Friends Group for Action of Blood Borne Viruses Co-Chairs, Tim Wilson, MP and Senator Louise Pratt invite you to a Parliamentary Morning Tea on Thursday 12 November.
Renewed calls for Needle & Syringe Programs in prisons ahead of International Drug Users Day

The Australian Injecting and Illicit Drug Users League (AIVL) and Hepatitis Australia are highlighting international calls for Needle and Syringe Programs (NSPs) in prisons, along with a greater focus on harm reduction initiatives, ahead of International Drug Users Day on 1 November.
Investment in hepatitis research needs to be accompanied by National Strategy implementation funding

6 October 2020 - Hepatitis Australia welcomes the Australian Government’s commitment to diverse hepatitis research, however we remain concerned that the 2019 Health Budget funding for hepatitis commitments is yet to hit the ground.
Investment in liver cancer medicines matched with prevention are changing Australian lives

6 October 2020 - Hepatitis Australia welcomes the Australian Government’s significant investment of $230 million to expand the listing of Tecentriq® and Avastin® (atezolizumab and bevacizumab) on the Pharmaceutical Benefits Scheme (PBS).